DrugPatentWatch Database Preview

Details for Patent: 7,989,448

« Back to Dashboard

Which drugs does patent 7,989,448 protect, and when does it expire?

Patent 7,989,448 protects TAVALISSE and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 7,989,448

Title:	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract:	The present disclosure provides compounds of the following formula, ##STR00001## and methods of using the compounds to inhibit cellular degranulation and to treat diseases associated therewith.
Inventor(s):	Singh; Rajinder (Belmont, CA), Bhamidipati; Somasekhar (Foster City, CA), Masuda; Esteban (Menlo Park, CA)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	12/268,218
Patent Claim Types: see list of patent claims	Use; Compound;

Drugs Protected by US Patent 7,989,448

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-001	Apr 17, 2018		RX	Yes	No				Y
Rigel Pharms Inc	TAVALISSE	fostamatinib disodium	TABLET;ORAL	209299-002	Apr 17, 2018		RX	Yes	Yes				Y

International Family Members for US Patent 7,989,448

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	451381
Australia	2006206458
Brazil	PI0606318
Canada	2591948
China	101115761